For 150,000 shillings, Joel Obore promises more than just a quick fix; he promises a “permanent” transformation. Obore, a ...
MedPage Today on MSN
Non-Ablative Treatment for BPH/LUTS Achieves Rapid, Sustained Improvements
Results with Optilume consistent in clinical trials and real world, regardless of prostate ...
Image courtesy of Prodeon Medical] Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross ...
Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive ...
Many unproven ‘claims’ put your health at risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results